Revealing True Targets for Next Gen Immunotherapies

Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK. They are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), CryptigenTM TSAs, designed to treat a broad patient population.

The Epitopea technology platform builds on their proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, which have been exclusively licensed from the Université de Montréal, along with the rights to exploit large sets of CryptigenTM TSAs in solid and haematological cancers

CEO  Jon Moore

Advent Contact  Raj Parekh

Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Private Companies
25 April 2022 in Epitopea, Press Release, Private Companies

Novel Cryptigen™ Technology unlocks full potential of Tumour Specific Antigens

Press Release.   CAMBRIDGE, UK and MONTREAL, CANADA, 25 April 2022 - Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens…
Read More